This drug can be our answer for antimicrobial resistance

December 1, 2019 | Blog

Antibiotic resistance is one of the man-made disasters and the “resistome” is a dynamic and mounting problem. Causes of the global resistome are overpopulation, enhanced global migration, increased use of antibiotics in clinics and animal production, selection pressure, poor sanitation, wildlife spread, and poor sewerage disposal system. Antibiotic treatment is one of the main approaches of modern medicine which is used to combat infections.

Why it is a Global Crisis??

Antibiotic resistance is a substantial economic burden to the whole world.
Antibiotic consumption worldwide increased 65% between 2000 and 2015 and doubled in lowand middle-income countries.
People still die because of lack of access to antibiotics than from resistant infections.
Unrestricted and inappropriate use of antibiotics will result in more infections that are untreatable, or more costly and difficult to treat.

WHO Guidelines to prevent Anti-Biotic Resistance:

Take antibiotics according to the prescription of your doctor.
Do not take more than prescribed anti-biotics and ensure complete Course.
Do not save antibiotics for the next illness, discard any leftover medication.
Do not ask for antibiotics when there is no need.

Natural way to combat anti-biotic Resistance:

Fifatrol a multidrug combination with power of five phytomineral active compounds and 8 herbal extracts having the potential to fight against bacterial infections and the resistant strains of various pathogens.

Fifatrol a natural antibiotic: A study

Testing Sample- Fifatrol Tablets and its individual classical components namely Tribhuvan kirti rasa, Sanjeevani vati, Mrityunjaya Ras, Sudarshan Ras

Study conducted at- Department of Microbiology, AIIMS Bhopal

Objective of the study-

Determination of antibiotic susceptibility pattern of various microorganisms against the Fifatrol (MDC).
Determination of anti-microbial activity of Fifatrol against the various sensitive and resistant strains.
Determination of Minimal Inhibitory Concentration (MIC) and Minimal Bactericidal Concentration (MBC) for antibiotics.
In-vitro cytotoxic studies of the drug.

Bacterial Strains selected for study:

In this study four bacterial trains were taken of laboratory grade which includes Salmonella typhi, Staphylococcus aureus, Staphylococcus epidermis, Staphylococcus Saprophyticus except S.typhi which was clinically isolated for experimental estimation.

TABLE 1

MIC (The minimum dose required to inhibit the growth of pathogen) of FIFATROL TABLETS & various classical preparations against various pathogens.

BACTERIA	FIFATROL	SANJEEVANI	TRIBHUVAN KIRTI RAS	MRITYUNJAY RAS
Salmonella typhi	62.5 μg/ml	125 μg/ml	125 μg/ml	500 μg/ml
Staphylococcus aureus	125 μg/ml	500 μg/ml	0 μg/ml	0 μg/ml
Staphylococcus epidermis	125 μg/ml	31.3 μg/ml	7.81 μg/ml	7.81 μg/ml
Staphylococcus Saprophyticus	500 μg/ml	125 μg/ml	31.3 μg/ml	500 μg/ml

The study concludes:

Various classical preparations i.e. Tribhuvan kirti rasa, Sanjeevani vati, Mrityunjaya Ras showed inhibitory actions against selective pathogens where as fifatrol significantly inhibits the growth of all these pathogens mentioned above. Fifatrol inhibits the growth of various pathogens at different MIC dosage and remarkably inhibits the growth of S.typhi at lowest dose of 62.5 µg/ml.

Established Safety study:

Conducted at: Accuprec Research Labs Pvt. Ltd. Duration: 28 days

Dosage: 310 mg, 620 mg, 1240 mg/kg in wistar rats

Outcome: no abnormal findings from gross pathological examination of internal organs in all groups.

Formulation found to be safe at 310,620,1240 mg/kg when administered for 28 days.

Conclusion of the study:

Fifatrol is more susceptible to S.typhi, S.aureus, S.epidermis, S.saprophyticus at 1mg/ml concentration.
The study showed encouraging results with significant growth inhibitory effect present in fifatrol at lowest concentration of 62.5 µg/ml.
Fifatrol is effective against pathogens primarily causing upper respiratory tract infections enteric fever and sinusitis.

Note- Further investigation on enterobacteriaceae family i.e. E. coli, Enterococcus faecalis, P.mirabilis and other pathogens are still under ongoing clinical evaluation.